PEER-REVIEWED Publications 2012

1 Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke SW Worm, DA Kamara, P Reiss, E Fontas, S De Wit, W El-Sadr, A D´Arminio Monforte, M Law, A Phillips, L Ryom, NF Dabis, R Weber, C Sabin, JD Lundgren, and on behalf of the D:A:D Study Group 
J Infect Dis. 2012 Feb;205(4):535-9. abstract

2 Projected life expectancy of people with HIV according to timing of diagnosis. F Nakagawa, RK Lodwick, CJ Smith, R Smith, V Cambiano, J Lundgren, V Delpech, AN Phillips. 
AIDS. 2012 Jan 28;26(3):335-43. abstract

3 Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes : A cohort study. D Costagliola, R Lodwick, B Ledergerber, C Torti, A van Sighem, D Podzamcer, A Mocroft, et al. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group.
Lancet Infect Dis. 2012 Jan 28;26(3):315-323. abstract

4 Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. JD Kowalska, J Reekie, A Mocroft, P Reiss, B Ledergerber, J Gatell, AD Monforte, A Phillips, JD Lundgren, O Kirk; for the EuroSIDA study group. 
AIDS. 2012 Jan 28;26(3):315-32. abstract

5 Dampening the effect of drug resistance in HIV: a leap forward. JD Lundgren, JV Lazarus. 
Lancet Infect Dis. 2012 Feb;12(2):91-2. abstract

6 CD4 cell count and the risk of AIDS or death in HIV-infected adults on cART with a suppressed viral load: A longitudinal cohort study from COHERE. J Young, M Psichogiou, L Meyer, S Ayayi, S Grabar, F Raffi, P Reiss, B Gazzard, M Sharland, F Gutierrez, N Obel, O Kirk, JM Miro, H Furrer, A Castagna, S De Wit, J Muñoz, J Kjær, C Colin, J Grarup, G Chêne, H Bucher. 
PLoS Med. 2012 Mar;9(3):e1001194. abstract

7 All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. C Lewden, V Bouteloup, S De Wit, C Sabin, A Mocroft, JC Wasmuth, A van Sighem, O Kirk, N Obel, G Panos, J Ghosn, F Dabis, M Mary-Krause, C Leport, S Perez-Hoyos, P Sobrino-Vegas, C Stephan, A Castagna, A Antinori, A d'Arminio Monforte, C Torti, C Mussini, V Isern, A Calmy, R Teira, M Egger, J Grarup, G Chêne.  
Int J Epidemiol. 2012 Apr;41(2):433-445. abstract

8 Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. A Rodger, A Phillips, T Bruun, M Weait, P Vernazza, S Collins, V Estrada, J Van Lunzen, GM Corbelli, J Lundgren.  
BMC Public Health. 2012 Apr 20;12(1):296. abstract

9 HIV Therapies and the kidney: Some good, some not so good? L Ryom, A Mocroft, J Lundgren.  
Curr HIV/AIDS Rep. 2012 Jun;9(2):111-20. abstract

10 The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI(*). A Cozzi-Lepri, R Paredes, AN Phillips, B Clotet, J Kjaer, V Von Wyl, G Kronborg, A Castagna, Jr Bogner, JD Lundgren for EuroSIDA in EuroCoord. 
HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x. abstract

11 HIV in men who have sex with men in sub-Saharan Africa. ML Sabin, JV Lazarus, L Frescura, W Gill, M Mahy. 
Lancet Infect Dis. 2012 Jul;12(7):505-6. abstract

12 Population mobility and the changing epidemics of HIV-2 in Portugal. A Carvalho, E Valadas, T Branco, MJ Aleixo, J Mendes, M Doroana, R Marques, C Carvalho, MJ Águas, A Sarmento, R Sarmento e Castro, F Antunes, JV Lazarus, H Barros. 
HIV Med. 2012 Apr;13(4):219-25. abstract

13 Mapping Global Fund investments in harm reduction from 2002 to 2009. J Bridge, BM Hunter, R Atun, JV Lazarus. 
Int J Drug Policy 2012 July;23(4):279-85. abstract

14 Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA Study. J Reekie, JD Kowalska, I Karpov, J Rockstroh, A Karlsson, A Rakhmanova, A Horban, O Kirk, JD Lundgren, A Mocroft; for EuroSIDA in EuroCoord. 
PLoS One. 2012;7(7):e41673. abstract

15 "E" is for everything else, not least for expanding HIV testing in Europe. J V Lazarus, J D Lundgren.  
Bulletin World Health Organ 2012;90:634-634A article

16 HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethlarginine, a novel marker of endothelial dysfunction. JV Baker, J Neuhaus, D Duprez, M Freiberg, JI Bernardino, AD Badley, DE Nixon, JD Lundgren, RP Tracy, JD Neaton; INSIGHT SMART Study Group. 
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):128-34. abstract

17 Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. JU Jensen, L Hein, B Lundgren, MH Bestle, T Mohr, MH Andersen, KJ Thornberg, J Løken, M Steensen, Z Fox, H Tousi, P Søe-Jensen, AO Lauritsen, DG Strange, N Reiter, K Thormar, PC Fjeldborg, KM Larsen, NE Drenk, ME Johansen, LR Nielsen, C Ostergaard, J Kjær, J Grarup, JD Lundgren; The Procalcitonin And Survival Study (PASS) Group.  
BMJ Open. 2012 Mar 11;2(2). abstract

18 Health Systems Global, the new international society for health systems research. D Kraushaar, MP Kieny, JV Lazarus, R Bermejo 3rd, S Abimbola, N Prashanth, W Flores, F Ssengooba, D Maceira. 
Health Policy Plan. 2012 Oct;27(7):535-40. article

19 Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. K Petoumenos, SW Worm, E Fontas, R Weber, S De Wit, M Bruyand, P Reiss, W El-Sadr, A d'Arminio Monforte, N Friis-Møller, JD Lundgren, MG Law on behalf of the D:A:D Study Group.
Journal of the International AIDS Society 2012, 15:17426 article

20 Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. R Weber, M Ruppik, M Rickenbach, A Spoerri, H Furrer, M Battegay, M Cavassini, A Calmy, E Bernasconi, P Schmid, M Flepp, J Kowalska, B Ledergerber and the Swiss HIV Cohort Study (SHCS).
HIV Med. 2012 Sep 24. doi: 10.1111/j. 1468-1293.2012.01051.x. article

21 Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. DA Duprez, J Neuhaus, LH Kuller, R Tracy, W Belloso, S De Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, D Nixon, NI Paton, RJ Prineas, JD Neaton for the INSIGHT SMART Study Group.
PLoS One. 2012;7(9):e44454. abstract

22 Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. D Podlekareva, J Reekie, A Mocroft, M Losso, A Rakhmanova, E Bakowska, IA Karpov, J Lazarus, J Gatell, JD Lundgren, O Kirk.
BMC Infect Dis. 2012 Sep 25;12(1):229. abstract

23 HCV viremia increases the incidence of chronic kidney disease in HIV-infected patients. L Peters, D Grint, JD Lundgren, JK Rockstroh, V Soriano, P Reiss, A Grzeszczuk, H Sambatakou, A Mocroft, O Kirk; for EuroSIDA in EuroCoord.
AIDS. 2012 Sep 24;26(15):1917-1926. abstract

24 Long-term effects of intermittent IL-2 in HIV infection: Extended follow-up of the INSIGHT STALWART Study. N Markowitz, G Lopardo, D Wentworth, D Gey, A Babiker, L Fox, J Tavel; STALWART Study Group.
PLoS One. 2012;7(10):e47506. abstract

25 Refinement of prompts for rapid response teams. JU Jensen, M Bestle, J Lundgren.
Crit Care Med. 2012 Jul;40(7):2241-2. abstract

26 Aging with HIV in Africa: the challenges of living longer. J Negin, T Bärnighausen, JD Lundgren, EJ Mills.
AIDS. 2012 Jul31;26 Suppl 1:S1-5. abstract

27 System to classify cause of deaths in HIV-positive persons: time to harmonize. JD Kowalska, C Smith, JD Lundgren.
AIDS. 2012 Sep 10;26(14):1835-6. abstract

28 The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. A Mocroft, WP Bannister, O Kirk, JD Kowalska, P Reiss, A d'Arminio Monforte, J Gatell, M Fisher, H Trocha, A Rakhmanova, JD Lundgren; the EuroSIDA Study in EuroCoord.
Antivir Ther. 2012;17(7):1291-1300. abstract

29 Key barriers affecting the use of modern contraceptives among women in Albania - a qualitative study. KK Nielsen, SF Nielsen, R Butler, JV Lazarus.
Reproductive Health Matters 2012;20(40):160-167. abstract

30 Making the first global society for health systems research truly global. J Lazarus, D Balabanova, M McKee.
Cent Eur J Public Health 2012; 20 (4): 299-304. abstract

31 Collaboration in the provision of mental health care services: a cross-sectional survey of Lithuanian general practitioners. L Jaruseviciene, JV Lazarus, N Zemaitiene, G Jarusevicius, L Valius.
Healthmed. 2012; 6(5):1583-1589. abstract

32 A study of antibiotic prescribing: the experience of Lithuanian and Russian GPs. L Jaruseviciene, R Radzeviciene, JV Lazarus, A Jurgutis, I Ovhed, EL Strandberg, L Bjerrum.
Central European Journal of Medicine. 2012 (6 September 2012), pp. 1-10. abstract

33 Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration.
HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
Antivir Ther. 2012;17(8):1541-50. Epub 2012 Jul 24. abstract

34 Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults.
A Mocroft, J Neuhaus, L Peters, L Ryom, M Bickel, D Grint, J Koirala, A Szymczak, J Lundgren, MJ Ross, CM Wyatt; INSIGHT SMART Study Group; ESPRIT Study Group.
PLoS One. 2012;7(7):e40245. Epub 2012 Jul 20. abstract

35 Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. MT May, RS Hogg, AC Justice, BE Shepherd, D Costagliola, B Ledergerber, R Thiébaut, MJ Gill, O Kirk, A van Sighem, MS Saag, G Navarro, P Sobrino-Vegas, F Lampe, S Ingle, JL Guest, HM Crane, A d'Arminio Monforte, JJ Vehreschild, JA Sterne; the Collaborating Cohorts and Study Groups.
Int J Epidemiol. 2012 Dec;41(6):1807-20. Epub 2012 Nov 12.abstract

36 Pyomyositis in the upper Negro river basin, Brazilian Amazonia. Borges AH,  Faragher B, Lalloo DG.  
Trans R Soc Trop Med Hyg. 2012 Sep;106(9):532-7. abstract

37 Prophylactic platelets in dengue: survey responses highlight lack of an evidence base Whitehorn J, Roche RR, Guzman MG, Martinez E, Gomez WV, Nainggolan L, Laksono IS, Mishra A, Lum L, Faiz A, Sall A, Dawurung J, Borges A, Leo YS, Blumberg L, Bausch DG, Kroeger A, Horstick O, Thwaites G, Wertheim H, Larsson M, Hien TT, Peeling R, Wills B, Simmons C, Farrar J. 
PLoS Negl Trop Dis. 2012;6(6):e1716. abstract

38 Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. V von Wyl, V Cambiano, MR Jordan, S Bertagnolio, A Miners, D Pillay, J Lundgren, AN Phillips. 
PLoS One. 2012;7(8):e42834. abstract

39 Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe. F Nakagawa for the PLATO II group for COHERE in EuroCoord.
J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. article